ゲノミクス市場：製品・サービス（消耗品、機器、システム、ソフトウェア）、技術（シーケンス、PCR、マイクロアレイ）、研究タイプ（エピゲノム、バイオマーカー探索）、アプリケーション（創薬、診断、農業）-2028年までの世界予測

Genomics Market by Product & Service (Consumables, Instrument, System & Software), Technology (Sequencing, PCR, Microarray), Study Type (Epigenomics, Biomarker Discovery), Application (Drug Discovery, Diagnostic, Agriculture) - Global Forecast to 2028

世界のゲノム市場は、2023年の462億米ドルから2028年には831億米ドルに達すると予測され、2023年から2028年の予測期間中に12.4％のCAGRで推移すると予測されています。.シーケンサー技術の継続的な発展とゲノミク... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年4月27日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	395	291	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界のゲノム市場は、2023年の462億米ドルから2028年には831億米ドルに達すると予測され、2023年から2028年の予測期間中に12.4％のCAGRで推移すると予測されています。.シーケンサー技術の継続的な発展とゲノミクスに対するより深い理解により、疾患検出におけるバイオマーカーの効率は向上しています。正確な診断と個別化医療は生存率を高め、国民健康保険制度の財政負担を軽減するため、世界中の政府がゲノム科学に多額の投資を行っており、ゲノム市場の主要プレーヤーは互いに、また中小企業、バイオ医薬品会社、その他のエンドユーザーとの協力関係を深め、世界中で製品の提供を拡大していることが市場成長を促進しています。しかし、熟練した研究者の不足、倫理的な問題、大量のゲノムデータの安全な保存に関連する問題が、市場の成長を妨げています。

製品・サービス分野では、消耗品・試薬が最も大きなシェアを占めると予想される。
製品・サービスに基づき、ゲノム市場は消耗品・試薬、サービス、機器・システム・ソフトウェアに区分される。2022年、消耗品・試薬分野はゲノミクス市場で最大のシェアを占めています。診断、個別化医療、創薬、動物研究など、さまざまな分野でゲノミクスの用途が拡大していることから、予測期間中に消耗品および試薬の市場を押し上げると予想されます。
マイクロアレイ分野は、ゲノミクス市場におけるテクノロジー分野の中で最も低い市場成長率を占めている
技術別に見ると、ゲノミクス市場は、シーケンサー、PCR、マイクロアレイ、フローサイトメトリー、その他の技術に分類されます。2022年には、マイクロアレイ技術が最も低い市場成長率を占めています。マイクロアレイ技術は、遺伝子発見、疾病診断、創薬、がん研究、毒物学研究などに応用されています。しかし、シーケンサー技術の採用が進んでいるため、この市場の成長はある程度制限されるでしょう。
欧州はゲノミクス市場において2番目に大きな地域である
ゲノミクス市場は、北米、欧州、アジア太平洋地域、中南米（LATAM）、中東・アフリカ（MEA）に区分されます。北米に次いで、欧州では、ゲノミクスに関する広範な開発、NGSベースの診断テストの発売、ゲノミクス製品の使用に関する業界プレーヤーや研究機関の協力が、同地域の市場成長を促進すると予測されます。

本報告書のために実施した一次インタビューは、以下のように分類される：

- 回答者別供給側80％、需要側20
- 役職別マネージャー45％、CXO・ディレクタークラス30％、エグゼクティブ25％。
- 地域別北米：30％、欧州：20％、アジア太平洋：35％、中南米：10％、中近東・アフリカ：5％。

ゲノミクス市場の著名なプレーヤーは、Illumina, Inc.（米国）、Thermo Fisher Scientific, Inc.（米国）、Danaher Corporation（米国）、QIAGEN N.V. （ドイツ）、Agilent Technologies, Inc（米国）、PerkinElmer Inc（米国）、 F. Hoffmann-La Roche Ltd. （スイス）です。(スイス)です。

調査対象です：
本レポートは、ゲノミクス市場の詳細な情報を提供します。製品、アプリケーション、テクノロジー、研究タイプ、エンドユーザー、地域などの異なるセグメントにおける市場規模および将来の成長可能性を推定することを目的としています。また、主要な市場プレイヤーの会社概要や最近の開発状況、主要な市場戦略とともに、詳細な競合分析も行っています。

レポート購入の主なメリット
本レポートは、ゲノミクス市場全体とそのサブセグメントについて、最も近似した収益数値を提供することで、市場リーダー/新規参入者の助けとなります。また、利害関係者が競争環境をよりよく理解し、より多くの洞察を得ることで、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てることができるようになると考えられます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、課題、トレンド、機会に関する情報を提供することを可能にします。

本レポートでは、以下のポイントについて考察しています：
- 主要な推進要因の分析（ゲノミクスプロジェクトを支援する政府資金の増加、ウイルス性疾患および遺伝性疾患の発生率と有病率の上昇、がんの発生率の上昇とがん研究における次世代シーケンサーの応用の増加、ゲノミクス新興企業への投資の活発化、ゲノミクスの応用の成長）、ゲノミクス市場の成長に影響を与える機会（専門化/個別化医療におけるゲノミクスの利用）、課題（倫理的問題、訓練を受けた専門家の不足、大量データの安全な保存）、トレンド（ゲノミクスの技術的進歩のためのパートナーシップやコラボレーション、ゲノミクスにおけるAI）。
- 製品・サービスの開発/革新：新しく発売された製品やサービスに関する詳細なインサイトと、ゲノミクス市場の技術的評価。
- 市場開発：有利な市場に関する包括的な情報 - 本レポートでは、さまざまな地域にわたるゲノミクス市場を分析しています。
- 市場の多様化新製品・サービス、未開拓の地域、最近の開発状況、ゲノミクス市場への投資に関する詳細な情報を提供します。
- 競争力のある評価：Illumina, Inc.（米国）、Thermo Fisher Scientific, Inc.（米国）、Danaher Corporation（米国）、QIAGEN N.V.（ドイツ）、Agilent Technologies, Inc（米国）、PerkinElmer Inc（米国）、 F. Hoffmann-La Roche Ltd. （スイス）など主要企業の市場シェア、成長戦略、サービス提供について詳細に評価する。(スイス)などのゲノミクス市場に参入しています。また、本レポートは、関係者がゲノミクス市場の脈を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、および機会に関する情報を提供します。

ページTOPに戻る

1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 35
1.2.1 INCLUSIONS AND EXCLUSIONS 35
1.3 MARKET SCOPE 36
1.3.1 MARKETS COVERED 36
1.3.2 YEARS CONSIDERED 37
1.4 CURRENCY 37
1.5 LIMITATIONS 37
1.6 STAKEHOLDERS 38
1.7 SUMMARY OF CHANGES 38
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH APPROACH 39
FIGURE 1 RESEARCH DESIGN 39
2.1.1 PRIMARY RESEARCH 40
FIGURE 2 GENOMICS MARKET: PRIMARY RESPONDENTS 40
2.2 MARKET ESTIMATION METHODOLOGY 41
FIGURE 3 GENOMICS MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 41
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION) 42
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 43
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 43
2.3 MARKET GROWTH RATE PROJECTIONS 44
FIGURE 6 GENOMICS MARKET: CAGR PROJECTIONS 45
FIGURE 7 GENOMICS MARKET: GROWTH ANALYSIS OF DEMAND-SIDE FACTORS 46
2.4 DATA TRIANGULATION 47
FIGURE 8 DATA TRIANGULATION METHODOLOGY 47
2.5 RESEARCH ASSUMPTIONS 48
2.6 RISK ANALYSIS 48
2.7 RECESSION IMPACT 49
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 49
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 49
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 49
3 EXECUTIVE SUMMARY 51
FIGURE 9 GENOMICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 51
FIGURE 10 GENOMICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 52
FIGURE 11 GENOMICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 52
FIGURE 12 GENOMICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 53
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF GENOMICS MARKET 54
4 PREMIUM INSIGHTS 55
4.1 GENOMICS MARKET OVERVIEW 55
FIGURE 14 RISING PREVALENCE OF GENETIC DISORDERS TO DRIVE MARKET 55
4.2 NORTH AMERICA: GENOMICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022) 56
FIGURE 15 CONSUMABLES AND REAGENTS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 56
4.3 GENOMICS MARKET SHARE, BY APPLICATION, 2023 VS. 2028 57
FIGURE 16 DRUG DISCOVERY AND DEVELOPMENT SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2028 57
4.4 GENOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 57
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 57
5 MARKET OVERVIEW 58
5.1 INTRODUCTION 58
5.2 MARKET DYNAMICS 58
FIGURE 18 GENOMICS MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS 58
TABLE 4 GENOMICS MARKET: IMPACT ANALYSIS OF DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS 59
5.2.1 DRIVERS 60
5.2.1.1 Increasing government funding to support genomics projects 60
5.2.1.2 Rising incidence and prevalence of viral diseases and genetic disorders 60
FIGURE 19 BURDEN OF HIV INFECTIONS, BY REGION, 2021 61
5.2.1.3 Growing incidence of cancer and increasing applications of next-generation sequencing in cancer research 61
TABLE 5 CANCER INCIDENCE, 2020 VS. 2040 62
5.2.1.4 Robust investments in genomics startups 62
5.2.1.5 Growing applications of genomics 63
5.2.2 OPPORTUNITIES 63
5.2.2.1 Use of genomics in specialized/personalized medicine 63
5.2.3 CHALLENGES 64
5.2.3.1 Ethical issues 64
5.2.3.2 Dearth of trained professionals 64
5.2.3.3 Secure storage of large volumes of sequenced data 64
5.2.4 TRENDS 65
5.2.4.1 Partnerships and collaborations for technological advancements in genomics 65
5.2.4.2 AI in genomics 66
5.3 TECHNOLOGY ANALYSIS 67
TABLE 6 COMPARISON OF SANGER SEQUENCING AND NGS 67
TABLE 7 COMPARISON OF PCR TECHNOLOGIES 68
5.4 VALUE CHAIN ANALYSIS 69
FIGURE 20 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING SEQUENCING AND ANALYSIS PHASES 69
5.5 REGULATORY ANALYSIS 69
5.5.1 NORTH AMERICA 69
5.5.1.1 US 69
TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION 70
TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 71
5.5.1.2 Canada 71
5.5.2 EUROPE 71
5.5.3 ASIA PACIFIC 72
5.5.3.1 China 72
TABLE 10 CHINA: CLASSIFICATION OF MEDICAL DEVICES 72
5.5.3.2 Japan 72
5.5.3.3 India 73
5.5.4 LATIN AMERICA 73
5.5.5 MIDDLE EAST 73
5.6 ECOSYSTEM ANALYSIS OF GENOMICS MARKET 74
FIGURE 21 ECOSYSTEM ANALYSIS OF GENOMICS MARKET 74
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 74
FIGURE 22 REVENUE SHIFT AND NEW REVENUE POCKETS 74
5.8 PRICING ANALYSIS 75
5.8.1 AVERAGE SELLING PRICE OF NGS PRODUCTS 75
TABLE 11 AVERAGE SELLING PRICE OF NGS SYSTEMS, BY KEY PLAYER (2022) 75
5.8.2 AVERAGE SELLING PRICE OF PCR PRODUCTS 75
TABLE 12 AVERAGE SELLING PRICE OF PCR SYSTEMS, BY KEY PLAYER (2022) 75
5.8.3 AVERAGE SELLING PRICE TREND ANALYSIS 76
FIGURE 23 GENOME SEQUENCING PRICING TREND 76
5.9 KEY CONFERENCES AND EVENTS IN 2023–2024 76
TABLE 13 GENOMICS MARKET: LIST OF CONFERENCES AND EVENTS 76
5.10 PORTER’S FIVE FORCES ANALYSIS 77
TABLE 14 GENOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS 77
5.10.1 THREAT OF NEW ENTRANTS 78
5.10.2 THREAT OF SUBSTITUTES 78
5.10.3 BARGAINING POWER OF SUPPLIERS 78
5.10.4 BARGAINING POWER OF BUYERS 78
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 78
5.11 PATENT ANALYSIS 79
FIGURE 24 PATENT APPLICATIONS FOR GENOMICS (NEXT-GENERATION SEQUENCING) MARKET, JANUARY 2012–MARCH 2023 79
TABLE 15 INDICATIVE LIST OF PATENTS IN GENOMICS (NEXT-GENERATION SEQUENCING) MARKET 80
FIGURE 25 PATENT APPLICATIONS FOR GENOMICS (POLYMERASE CHAIN REACTION) MARKET, JANUARY 2012–MARCH 2023 81
TABLE 16 INDICATIVE LIST OF PATENTS IN GENOMICS (POLYMERASE CHAIN REACTION) MARKET 81
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 82
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF GENOMICS PRODUCTS AND SERVICES 82
FIGURE 27 BUYING CRITERIA FOR GENOMICS PRODUCTS 83
6 GENOMICS MARKET, BY PRODUCT & SERVICE 84
6.1 INTRODUCTION 85
TABLE 17 GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 85
6.2 CONSUMABLES AND REAGENTS 85
6.2.1 GROWING APPLICATIONS OF GENOMICS IN VARIOUS FIELDS TO DRIVE ADOPTION 85
TABLE 18 GENOMICS CONSUMABLES AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 86
TABLE 19 NORTH AMERICA: GENOMICS CONSUMABLES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 20 EUROPE: GENOMICS CONSUMABLES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 21 ASIA PACIFIC: GENOMICS CONSUMABLES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
6.3 SERVICES 88
6.3.1 LACK OF IN-HOUSE EXPERTISE FOR INTERPRETATION OF GENOMICS DATA TO BOOST MARKET FOR OUTSOURCING SERVICES 88
TABLE 22 GENOMICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 23 NORTH AMERICA: GENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 24 EUROPE: GENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 25 ASIA PACIFIC: GENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
6.4 INSTRUMENTS, SYSTEMS, AND SOFTWARE 91
6.4.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH 91
TABLE 26 LIST OF COMPANIES OFFERING MICROARRAY SCANNERS 92
TABLE 27 GENOMICS INSTRUMENTS, SYSTEMS, AND SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 28 NORTH AMERICA: GENOMICS INSTRUMENTS, SYSTEMS, AND SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 29 EUROPE: GENOMICS INSTRUMENTS, SYSTEMS, AND SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 30 ASIA PACIFIC: GENOMICS INSTRUMENTS, SYSTEMS, AND SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
7 GENOMICS MARKET, BY TECHNOLOGY 95
7.1 INTRODUCTION 96
TABLE 31 GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 96
7.2 SEQUENCING 96
7.2.1 LAUNCH OF NEW NGS PLATFORMS AND LOWER COST OF SEQUENCING TO DRIVE MARKET 96
TABLE 32 SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 33 NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 34 EUROPE: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 35 ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
7.3 PCR 99
7.3.1 USE OF PCR TECHNOLOGIES FOR DRUG DISCOVERY TO PROPEL MARKET 99
TABLE 36 PCR MARKET, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 37 NORTH AMERICA: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 38 EUROPE: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 39 ASIA PACIFIC: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
7.4 FLOW CYTOMETRY 102
7.4.1 APPLICATION OF FLOW CYTOMETRY IN AGRIGENOMICS TO SUPPORT MARKET GROWTH 102
TABLE 40 FLOW CYTOMETRY MARKET, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 41 NORTH AMERICA: FLOW CYTOMETRY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 42 EUROPE: FLOW CYTOMETRY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 43 ASIA PACIFIC: FLOW CYTOMETRY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
7.5 MICROARRAYS 104
7.5.1 HIGH ADOPTION OF NGS TO LIMIT GROWTH OF MICROARRAY TECHNOLOGIES 104
TABLE 44 MICROARRAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 45 NORTH AMERICA: MICROARRAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 46 EUROPE: MICROARRAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 47 ASIA PACIFIC: MICROARRAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106
7.6 OTHER TECHNOLOGIES 106
TABLE 48 OTHER TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 49 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 50 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 51 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
8 GENOMICS MARKET, BY APPLICATION 109
8.1 INTRODUCTION 110
TABLE 52 GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
8.2 DRUG DISCOVERY AND DEVELOPMENT 110
8.2.1 LARGEST APPLICATION SEGMENT OF GENOMICS MARKET 110
TABLE 53 GENOMICS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 54 NORTH AMERICA: GENOMICS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 55 EUROPE: GENOMICS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 56 ASIA PACIFIC: GENOMICS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 112
8.3 DIAGNOSTICS 113
8.3.1 GROWING APPLICATIONS OF GENOMICS IN DIAGNOSTICS FIELD TO PROPEL MARKET 113
TABLE 57 GRANTS, BY CANCER TYPE (AS OF JANUARY 2023) 113
TABLE 58 GENOMICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 115
TABLE 59 NORTH AMERICA: GENOMICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 60 EUROPE: GENOMICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 61 ASIA PACIFIC: GENOMICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 116
8.4 AGRICULTURE AND ANIMAL RESEARCH 117
8.4.1 GENOMICS HELPS IMPROVE PRODUCTIVITY OF CROPS AND LIVESTOCK 117
TABLE 62 GENOMICS MARKET FOR AGRICULTURE AND ANIMAL RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 63 NORTH AMERICA: GENOMICS MARKET FOR AGRICULTURE AND ANIMAL RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 64 EUROPE: GENOMICS MARKET FOR AGRICULTURE AND ANIMAL RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 65 ASIA PACIFIC: GENOMICS MARKET FOR AGRICULTURE AND ANIMAL RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 119
8.5 OTHER APPLICATIONS 119
TABLE 66 GENOMICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 67 NORTH AMERICA: GENOMICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 68 EUROPE: GENOMICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 69 ASIA PACIFIC: GENOMICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 121
9 GENOMICS MARKET, BY STUDY TYPE 122
9.1 INTRODUCTION 123
TABLE 70 GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 123
9.2 FUNCTIONAL GENOMICS 123
9.2.1 INCREASED GENOMIC STUDIES TO POSITIVELY INFLUENCE MARKET GROWTH 123
TABLE 71 GENOMICS MARKET FOR FUNCTIONAL GENOMICS, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 72 NORTH AMERICA: GENOMICS MARKET FOR FUNCTIONAL GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 73 EUROPE: GENOMICS MARKET FOR FUNCTIONAL GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 74 ASIA PACIFIC: GENOMICS MARKET FOR FUNCTIONAL GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 125
9.3 BIOMARKER DISCOVERY 126
9.3.1 RISE IN PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH 126
TABLE 75 GENOMICS MARKET FOR BIOMARKER DISCOVERY, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 76 NORTH AMERICA: GENOMICS MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 77 EUROPE: GENOMICS MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 78 ASIA PACIFIC: GENOMICS MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 128
9.4 PATHWAY ANALYSIS 128
9.4.1 DEVELOPMENT OF NEXT-GENERATION THERAPIES TO DRIVE MARKET 128
TABLE 79 GENOMICS MARKET FOR PATHWAY ANALYSIS, BY REGION, 2021–2028 (USD MILLION) 129
TABLE 80 NORTH AMERICA: GENOMICS MARKET FOR PATHWAY ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 81 EUROPE: GENOMICS MARKET FOR PATHWAY ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 82 ASIA PACIFIC: GENOMICS MARKET FOR PATHWAY ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION) 130
9.5 EPIGENOMICS 131
9.5.1 INCREASE IN INVESTMENTS FOR EPIGENETICS RESEARCH TO SUPPORT MARKET GROWTH 131
TABLE 83 GENOMICS MARKET FOR EPIGENOMICS, BY REGION, 2021–2028 (USD MILLION) 131
TABLE 84 NORTH AMERICA: GENOMICS MARKET FOR EPIGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 85 EUROPE: GENOMICS MARKET FOR EPIGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 86 ASIA PACIFIC: GENOMICS MARKET FOR EPIGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 133
9.6 OTHER STUDY TYPES 133
TABLE 87 GENOMICS MARKET FOR OTHER STUDY TYPES, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 88 NORTH AMERICA: GENOMICS MARKET FOR OTHER STUDY TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 89 EUROPE: GENOMICS MARKET FOR OTHER STUDY TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 90 ASIA PACIFIC: GENOMICS MARKET FOR OTHER STUDY TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 135
10 GENOMICS MARKET, BY END USER 136
10.1 INTRODUCTION 137
TABLE 91 GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 137
10.2 HOSPITALS AND CLINICS 137
10.2.1 INCREASED APPLICATION IN DISEASE DIAGNOSIS AND TREATMENT TO DRIVE MARKET 137
TABLE 92 GENOMICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 93 NORTH AMERICA: GENOMICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 94 EUROPE: GENOMICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 95 ASIA PACIFIC: GENOMICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 140
10.3 ACADEMIC AND RESEARCH INSTITUTES 140
10.3.1 INCREASE IN RESEARCH INTENSITY TO DRIVE USE OF GENOMICS PRODUCTS AMONG ACADEMIC AND RESEARCH INSTITUTES 140
TABLE 96 GENOMICS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 141
TABLE 97 NORTH AMERICA: GENOMICS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 98 EUROPE: GENOMICS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 99 ASIA PACIFIC: GENOMICS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 142
10.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 143
10.4.1 GROWING IMPORTANCE OF BIOMARKERS FOR DRUG DISCOVERY TO DRIVE ADOPTION OF GENOMICS PRODUCTS AND SERVICES AMONG PHARMA AND BIOTECH COMPANIES 143
TABLE 100 GENOMICS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 143
TABLE 101 NORTH AMERICA: GENOMICS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 102 EUROPE: GENOMICS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 103 ASIA PACIFIC: GENOMICS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 145
10.5 OTHER END USERS 145
TABLE 104 GENOMICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 146
TABLE 105 NORTH AMERICA: GENOMICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 106 EUROPE: GENOMICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 107 ASIA PACIFIC: GENOMICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 147
11 GENOMICS MARKET, BY REGION 148
11.1 INTRODUCTION 149
TABLE 108 GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 149
11.2 NORTH AMERICA 149
FIGURE 28 NORTH AMERICA: GENOMICS MARKET SNAPSHOT 150
TABLE 109 NORTH AMERICA: GENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 110 NORTH AMERICA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 151
TABLE 111 NORTH AMERICA: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 152
TABLE 112 NORTH AMERICA: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 152
TABLE 113 NORTH AMERICA: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 153
TABLE 114 NORTH AMERICA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 153
11.2.1 US 153
11.2.1.1 US dominates North American genomics market 153
TABLE 115 US: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 155
TABLE 116 US: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 155
TABLE 117 US: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 156
TABLE 118 US: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 156
TABLE 119 US: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 157
11.2.2 CANADA 157
11.2.2.1 Increasing research in genomics to drive market 157
TABLE 120 CANADA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 158
TABLE 121 CANADA: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 158
TABLE 122 CANADA: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 159
TABLE 123 CANADA: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 159
TABLE 124 CANADA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 160
11.2.3 NORTH AMERICA: RECESSION IMPACT 160
11.3 EUROPE 160
TABLE 125 EUROPE: GENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 126 EUROPE: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 161
TABLE 127 EUROPE: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 162
TABLE 128 EUROPE: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 162
TABLE 129 EUROPE: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 163
TABLE 130 EUROPE: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 163
11.3.1 GERMANY 164
11.3.1.1 Increasing awareness of NGS to boost market growth 164
TABLE 131 GERMANY: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 164
TABLE 132 GERMANY: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 165
TABLE 133 GERMANY: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165
TABLE 134 GERMANY: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 166
TABLE 135 GERMANY: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 166
11.3.2 UK 166
11.3.2.1 Availability of government funding and strategic collaborations with biotech firms to boost market growth 166
TABLE 136 UK: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 167
TABLE 137 UK: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 168
TABLE 138 UK: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 168
TABLE 139 UK: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 169
TABLE 140 UK: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 169
11.3.3 FRANCE 170
11.3.3.1 Increasing government investments in genomics to drive market 170
TABLE 141 FRANCE: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 170
TABLE 142 FRANCE: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 171
TABLE 143 FRANCE: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 171
TABLE 144 FRANCE: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 172
TABLE 145 FRANCE: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 172
11.3.4 ITALY 172
11.3.4.1 Favorable funding scenario to drive adoption of sequencing technologies 172
TABLE 146 ITALY: GENOMICS, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 173
TABLE 147 ITALY: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 173
TABLE 148 ITALY: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 174
TABLE 149 ITALY: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 174
TABLE 150 ITALY: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 175
11.3.5 SPAIN 175
11.3.5.1 Focus on expanding genomic research to support market growth 175
TABLE 151 SPAIN: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 175
TABLE 152 SPAIN: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 176
TABLE 153 SPAIN: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 176
TABLE 154 SPAIN: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 177
TABLE 155 SPAIN: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 177
11.3.6 REST OF EUROPE 178
TABLE 156 REST OF EUROPE: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 179
TABLE 157 REST OF EUROPE: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 179
TABLE 158 REST OF EUROPE: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 180
TABLE 159 REST OF EUROPE: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 180
TABLE 160 REST OF EUROPE: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 181
11.3.7 EUROPE: RECESSION IMPACT 181
11.4 ASIA PACIFIC 181
FIGURE 29 ASIA PACIFIC: GENOMICS MARKET SNAPSHOT 182
TABLE 161 ASIA PACIFIC: GENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 162 ASIA PACIFIC: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 183
TABLE 163 ASIA PACIFIC: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 184
TABLE 164 ASIA PACIFIC: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 184
TABLE 165 ASIA PACIFIC: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 185
TABLE 166 ASIA PACIFIC: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 185
11.4.1 CHINA 186
11.4.1.1 Fastest-growing market in Asia Pacific 186
TABLE 167 CHINA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 186
TABLE 168 CHINA: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 187
TABLE 169 CHINA: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 187
TABLE 170 CHINA: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 188
TABLE 171 CHINA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 188
11.4.2 JAPAN 188
11.4.2.1 Growing NGS market to support market growth 188
TABLE 172 JAPAN: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 189
TABLE 173 JAPAN: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 189
TABLE 174 JAPAN: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 190
TABLE 175 JAPAN: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 190
TABLE 176 JAPAN: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 191
11.4.3 INDIA 191
11.4.3.1 Emergence of local players and increasing adoption of genomics technologies to aid market growth 191
TABLE 177 INDIA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 192
TABLE 178 INDIA: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 193
TABLE 179 INDIA: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 193
TABLE 180 INDIA: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 193
TABLE 181 INDIA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 194
11.4.4 AUSTRALIA 194
11.4.4.1 Increase in precision medicine and academic studies to propel market growth 194
TABLE 182 AUSTRALIA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 195
TABLE 183 AUSTRALIA: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 195
TABLE 184 AUSTRALIA: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 195
TABLE 185 AUSTRALIA: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 196
TABLE 186 AUSTRALIA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 196
11.4.5 SOUTH KOREA 196
11.4.5.1 Government initiatives to favor market growth 196
TABLE 187 SOUTH KOREA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 197
TABLE 188 SOUTH KOREA: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 197
TABLE 189 SOUTH KOREA: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 198
TABLE 190 SOUTH KOREA: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 198
TABLE 191 SOUTH KOREA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 199
11.4.6 REST OF ASIA PACIFIC 199
TABLE 192 REST OF ASIA PACIFIC: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 199
TABLE 193 REST OF ASIA PACIFIC: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 200
TABLE 194 REST OF ASIA PACIFIC: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 200
TABLE 195 REST OF ASIA PACIFIC: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 201
TABLE 196 REST OF ASIA PACIFIC: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 201
11.4.7 ASIA PACIFIC: RECESSION IMPACT 201
11.5 LATIN AMERICA 202
11.5.1 EXPANSION OF KEY PLAYERS TO BOOST MARKET GROWTH 202
TABLE 197 LATIN AMERICA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 202
TABLE 198 LATIN AMERICA: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 203
TABLE 199 LATIN AMERICA: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 203
TABLE 200 LATIN AMERICA: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 204
TABLE 201 LATIN AMERICA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 204
11.5.2 LATIN AMERICA: RECESSION IMPACT 204
11.6 MIDDLE EAST AND AFRICA 205
11.6.1 INCREASING ADOPTION OF GENETIC TESTING AND RISING HIV & CANCER INCIDENCE TO DRIVE MARKET 205
TABLE 202 MIDDLE EAST AND AFRICA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 206
TABLE 203 MIDDLE EAST AND AFRICA: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 206
TABLE 204 MIDDLE EAST AND AFRICA: GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 207
TABLE 205 MIDDLE EAST AND AFRICA: GENOMICS MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION) 207
TABLE 206 MIDDLE EAST AND AFRICA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 208
11.6.2 MIDDLE EAST AND AFRICA: RECESSION IMPACT 208
12 COMPETITIVE LANDSCAPE 209
12.1 INTRODUCTION 209
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 210
FIGURE 30 GENOMICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 210
12.3 REVENUE ANALYSIS 211
FIGURE 31 REVENUE ANALYSIS OF KEY COMPANIES, 2020–2022 211
12.4 MARKET SHARE ANALYSIS 212
FIGURE 32 GENOMICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022 212
TABLE 207 GENOMICS MARKET: DEGREE OF COMPETITION 213
12.5 COMPANY EVALUATION MATRIX 214
12.5.1 STARS 214
12.5.2 EMERGING LEADERS 214
12.5.3 PERVASIVE PLAYERS 214
12.5.4 PARTICIPANTS 214
FIGURE 33 GENOMICS MARKET: COMPANY EVALUATION MATRIX, 2022 215
12.6 COMPETITIVE BENCHMARKING 216
12.6.1 OVERALL COMPANY FOOTPRINT (32 COMPANIES) 216
TABLE 208 PRODUCT & SERVICE AND REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 216
12.6.2 PRODUCT & SERVICE FOOTPRINT OF COMPANIES (32 COMPANIES) 217
TABLE 209 PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS 217
12.6.3 REGIONAL FOOTPRINT OF COMPANIES (32 COMPANIES) 218
TABLE 210 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 218
12.7 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES 220
12.7.1 PROGRESSIVE COMPANIES 220
12.7.2 STARTING BLOCKS 220
12.7.3 RESPONSIVE COMPANIES 220
12.7.4 DYNAMIC COMPANIES 220
FIGURE 34 GENOMICS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022 221
12.8 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 222
TABLE 211 GENOMICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 222
12.9 COMPETITIVE SCENARIO AND TRENDS 223
12.9.1 PRODUCT/SERVICE LAUNCHES 223
TABLE 212 GENOMICS MARKET: KEY PRODUCT/SERVICE LAUNCHES, JANUARY 2020–APRIL 2023 223
12.9.2 DEALS 224
TABLE 213 GENOMICS MARKET: KEY DEALS, JANUARY 2020–APRIL 2023 224
12.9.3 OTHER DEVELOPMENTS 225
TABLE 214 GENOMICS MARKET: OTHER KEY DEVELOPMENTS, JANUARY 2020–APRIL 2023 225
13 COMPANY PROFILES 226
13.1 MAJOR PLAYERS 226
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 ILLUMINA, INC. 226
TABLE 215 ILLUMINA, INC.: BUSINESS OVERVIEW 226
FIGURE 35 ILLUMINA, INC.: COMPANY SNAPSHOT (2022) 227
13.1.2 THERMO FISHER SCIENTIFIC INC. 242
TABLE 216 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 242
FIGURE 36 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 243
13.1.3 F. HOFFMANN-LA ROCHE LTD. 258
TABLE 217 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 258
FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 259
13.1.4 DANAHER CORPORATION 267
TABLE 218 DANAHER CORPORATION: BUSINESS OVERVIEW 267
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 268
13.1.5 QIAGEN N.V. 273
TABLE 219 QIAGEN N.V.: BUSINESS OVERVIEW 273
FIGURE 39 QIAGEN N.V.: COMPANY SNAPSHOT (2022) 274
13.1.6 AGILENT TECHNOLOGIES, INC. 282
TABLE 220 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 282
FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 283
13.1.7 PERKINELMER INC. 294
TABLE 221 PERKINELMER INC.: BUSINESS OVERVIEW 294
FIGURE 41 PERKINELMER INC.: COMPANY SNAPSHOT (2022) 295
13.1.8 BIO-RAD LABORATORIES, INC. 300
TABLE 222 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 300
FIGURE 42 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 301
13.1.9 EUROFINS SCIENTIFIC 306
TABLE 223 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 306
FIGURE 43 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022) 306
13.1.10 PACIFIC BIOSCIENCES 310
TABLE 224 PACIFIC BIOSCIENCES: BUSINESS OVERVIEW 310
FIGURE 44 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT (2022) 311
13.1.11 OXFORD NANOPORE TECHNOLOGIES PLC 317
TABLE 225 OXFORD NANOPORE TECHNOLOGIES PLC: BUSINESS OVERVIEW 317
FIGURE 45 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2022) 318
13.1.12 TAKARA BIO INC. 325
TABLE 226 TAKARA BIO INC.: BUSINESS OVERVIEW 325
FIGURE 46 TAKARA BIO INC.: COMPANY SNAPSHOT (2022) 326
13.1.13 BGI GROUP 333
TABLE 227 BGI GROUP: BUSINESS OVERVIEW 333
13.1.14 EPPENDORF AG 342
TABLE 228 EPPENDORF AG: BUSINESS OVERVIEW 342
FIGURE 47 EPPENDORF AG: COMPANY SNAPSHOT (2021) 343
13.1.15 MERCK KGAA 345
TABLE 229 MERCK KGAA: BUSINESS OVERVIEW 345
FIGURE 48 MERCK KGAA: COMPANY SNAPSHOT (2022) 346
13.1.16 BECTON, DICKINSON AND COMPANY 350
TABLE 230 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 350
FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 351
13.1.17 ABBOTT LABORATORIES 356
TABLE 231 ABBOTT LABORATORIES: BUSINESS OVERVIEW 356
FIGURE 50 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 357
13.1.18 23ANDME, INC. 361
TABLE 232 23ANDME, INC.: BUSINESS OVERVIEW 361
FIGURE 51 23ANDME, INC.: COMPANY SNAPSHOT (2021) 362
13.1.19 10X GENOMICS 364
TABLE 233 10X GENOMICS: BUSINESS OVERVIEW 364
FIGURE 52 10X GENOMICS: COMPANY SNAPSHOT (2022) 365
13.1.20 NEW ENGLAND BIOLABS 369
TABLE 234 NEW ENGLAND BIOLABS: BUSINESS OVERVIEW 369
13.1.21 PROMEGA CORPORATION 374
TABLE 235 PROMEGA CORPORATION: BUSINESS OVERVIEW 374
13.1.22 CREATIVE BIOGENE 380
TABLE 236 CREATIVE BIOGENE: BUSINESS OVERVIEW 380
13.1.23 NOVOGENE CO., LTD. 384
TABLE 237 NOVOGENE CO., LTD.: BUSINESS OVERVIEW 384
13.1.24 ULTIMA GENOMICS, INC. 386
TABLE 238 ULTIMA GENOMICS, INC. BUSINESS OVERVIEW 386
13.1.25 FREENOME HOLDINGS, INC. 387
TABLE 239 FREENOME HOLDINGS, INC.: BUSINESS OVERVIEW 387
13.2 OTHER PLAYERS 389
13.2.1 QUEST DIAGNOSTICS 389
13.2.2 MYRIAD GENETICS, INC. 390
13.2.3 PERSONALIS, INC. 391
13.2.4 HELIX OPCO, LLC 392
13.2.5 POLARIS GENOMICS 392
13.2.6 PHALANX BIOTECH GROUP 393
13.2.7 GENOMIQA PTY LTD 393
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 394
14.1 DISCUSSION GUIDE 394
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 399
14.3 CUSTOMIZATION OPTIONS 401
14.4 RELATED REPORTS 402
14.5 AUTHOR DETAILS 403

ページTOPに戻る

Table of Contents

Summary

The global genomics market is projected to reach USD 83.1 billion by 2028 from USD 46.2 billion in 2023, at a CAGR of 12.4% during the forecast period of 2023 to 2028. . Continuous developments in sequencing technologies and a better understanding of genomics have increased the efficiency of biomarkers in disease detection. Since precise diagnosis and personalized medicine increase survival rates as well as reduce the financial burden on national health insurance programs, governments across the globe are making significant investments in genome sciences, and key players in the genomics market are increasingly collaborating with each other as well as with smaller players, biopharmaceutical companies, and other end users to expand their product offerings across the globe which is promoting market growth. However, dearth of skilled players, ethical issues and the issues associated with secure storage of large volume genomics data is hampering market growth.

Consumables & Reagents is expected to account for the largest share for product and services segment.
Based on product and service, the genomics market is segmented into consumables and reagents, services, and instruments, systems, and software. In 2022, the consumables and reagents segment accounted for the largest share of the genomics market. The growing applications of genomics in various fields, such as diagnostics, personalized medicine, and drug discovery, animal research, are expected to boost the market for consumables and reagents during the forecast period.
The microarrays segment accounted for the lowest market growth of the technology segment in the genomics market
On the basis of technology, the genomics market is segmented into sequencing, PCR, microarrays, flow cytometry, and other technologies. In 2022, microarray technology accounted for the lowest market growth. Microarray technology has applications in gene discovery, disease diagnosis, drug discovery, cancer research, and toxicological research. However, the increasing adoption of sequencing technologies will limit the growth of this market to a certain extent.
Europe is the second largest region in the genomics market
The genomics market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). After North America, In Europe, extensive developments in genomics, the launch of NGS-based diagnostic tests, and collaborations among industry players and research institutes for the use of genomics products are projected to drive market growth in the region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%
• By Region: North America -30%, Europe -20%, Asia-Pacific -35%, Latin America -10%, and Middle East and Africa – 5%

Prominent Players of the genomics market are Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (US), PerkinElmer Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland).

Research Coverage:
This report provides a detailed picture of the genomics market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, technology, study type, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall genomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following pointers:
• Analysis of key drivers (Increasing government funding to support genomics projects, Rising incidence and prevalence of viral diseases and genetic disorders, Growing incidence of cancer and increasing applications of next-generation sequencing in cancer research, Robust investments in genomics startups, Growing applications of genomics), opportunities (use of genomics in specialized/personalized medicine), challenges (ethical issues, dearth of trained professionals, secure storage of large volume data), trends (Partnerships and collaborations for technological advancements in genomics, AI in genomics) influencing the growth of genomics market.
• Product & Service Development/Innovation: Detailed insights on newly launched product and services, and technological assessment of the genomics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the genomics market across varied regions.
• Market Diversification: Exhaustive information about new product and services, untapped geographies, recent developments, and investments in the genomics market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (US), PerkinElmer Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), among others in the genomics market. The report also helps stakeholders understand the pulse of genomics market and provides them information on key market drivers, restraints, challenges, and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（biomarker）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（biomarker）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?